Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Guidelines for submitting adverse event reports for publication.

William N Kelly1, Felix M Arellano, Joanne Barnes

  • 1William N. Kelly Consulting, Inc., Oldsmar, Florida 34677, USA. wnkelly@earthlink.net

Drug Safety
|May 3, 2007
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.

Pharmaceutical biology·2026
Same author

New Zealand green-lipped mussel (kuku).

Journal of primary health care·2026
Same author

Deciphering the miR-29c-3p / TET3 regulatory axis within the SARS-CoV-2-infected midbrain.

Virology·2026
Same author

Assessing Natural Health Product-Drug Interactions and Coding Feasibility: Analysis of a New Zealand General Population Dataset from an Online Market Research Panel.

Drug safety·2026
Same author

Pharmacovigilance Regulatory Requirements for the Natural Health Products (NHPs) Industry in World Health Organization-Defined High Health Expenditure Countries (2020): A Scoping Review.

Drug safety·2026
Same author

A Scoping Review of Case-Level Causality Assessment Tools Developed Between 2008 and 2023; Strengths, Weaknesses and Potential Future Improvements.

Drug safety·2026
This summary is machine-generated.

Publishing adverse event case reports is crucial for postmarketing surveillance. New guidelines aim to improve the quality and completeness of these reports for better drug safety assessment.

Area of Science:

  • Pharmacovigilance and Drug Safety
  • Medical Device Surveillance
  • Herbal and Complementary Medicine Monitoring

Background:

  • Publication of adverse event case reports is vital for postmarketing surveillance and identifying potential drug risks.
  • Deficiencies in published case reports often limit their value for assessing causality and understanding mechanisms.
  • Existing journal requirements for publishing adverse event reports are often minimal or non-existent.

Framework:

  • Development of standardized guidelines for reporting suspected adverse events associated with drugs and medical products.
  • Guidelines focus on essential information for differential diagnosis, causality assessment, and biological plausibility.
  • Endorsement by the International Society for Pharmacoepidemiology (ISPE) and the International Society of Pharmacovigilance (ISoP).

Related Experiment Videos

Implementation:

  • Recommendations for information to be included in case reports submitted for publication.
  • Encouraging biomedical journals to adopt and enforce these reporting guidelines.
  • Promoting the integration of these guidelines into healthcare professional education curricula.

Implications:

  • Enhancing the quality and utility of published adverse event case reports.
  • Improving the detection and evaluation of potential risks associated with medical products.
  • Strengthening postmarketing surveillance systems for better public health protection.